Judah Frommer

Stock Analyst at Morgan Stanley

(4.00)
# 595
Out of 5,044 analysts
182
Total ratings
60.9%
Success rate
7.73%
Average return

Stocks Rated by Judah Frommer

ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71$101
Current: $94.25
Upside: +7.17%
Trevi Therapeutics
Aug 21, 2025
Initiates: Overweight
Price Target: $18
Current: $10.54
Upside: +70.78%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25$26
Current: $30.05
Upside: -13.48%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46$43
Current: $27.07
Upside: +58.85%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22$24
Current: $13.16
Upside: +82.37%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31$22
Current: $31.31
Upside: -29.73%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8$6
Current: $11.96
Upside: -49.83%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81$106
Current: $87.52
Upside: +21.12%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $17.08
Upside: +104.92%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.10
Upside: +520.53%
Assumes: Equal-Weight
Price Target: $3
Current: $3.04
Upside: -1.32%
Reiterates: Outperform
Price Target: $40
Current: $2.34
Upside: +1,609.40%
Reiterates: Outperform
Price Target: $13
Current: $2.29
Upside: +467.69%
Reiterates: Outperform
Price Target: $30
Current: $69.93
Upside: -57.10%
Reiterates: Outperform
Price Target: $23
Current: $31.63
Upside: -27.28%
Reiterates: Neutral
Price Target: $50
Current: $67.48
Upside: -25.90%
Reiterates: Neutral
Price Target: $141
Current: $24.22
Upside: +482.16%
Reiterates: Outperform
Price Target: $9
Current: $5.96
Upside: +51.01%
Maintains: Outperform
Price Target: $21$22
Current: $36.14
Upside: -39.13%
Maintains: Outperform
Price Target: $8$7
Current: $5.60
Upside: +25.00%
Downgrades: Neutral
Price Target: $11$8
Current: $10.00
Upside: -20.00%
Reiterates: Outperform
Price Target: $46
Current: $68.49
Upside: -32.84%
Upgrades: Neutral
Price Target: $6.5$7
Current: $3.04
Upside: +130.26%
Maintains: Outperform
Price Target: $51$55
Current: $70.00
Upside: -21.43%
Reiterates: Outperform
Price Target: $46
Current: $165.29
Upside: -72.17%
Maintains: Outperform
Price Target: $47$49
Current: $100.13
Upside: -51.06%
Maintains: Neutral
Price Target: $328$370
Current: $924.16
Upside: -59.96%
Maintains: Outperform
Price Target: $24$31
Current: $74.31
Upside: -58.28%
Maintains: Outperform
Price Target: $65$76
Current: $75.89
Upside: +0.14%
Assumes: Neutral
Price Target: $182
Current: $101.92
Upside: +78.57%
Assumes: Outperform
Price Target: $107
Current: $102.70
Upside: +4.19%
Maintains: Neutral
Price Target: $90$95
Current: $124.43
Upside: -23.65%
Initiates: Outperform
Price Target: $18
Current: $18.47
Upside: -2.54%
Maintains: Outperform
Price Target: $93$116
Current: $160.67
Upside: -27.80%
Maintains: Outperform
Price Target: $31$38
Current: $92.42
Upside: -58.88%
Maintains: Neutral
Price Target: $18$22
Current: $106.80
Upside: -79.40%
Maintains: Neutral
Price Target: $33$35
Current: $67.69
Upside: -48.29%